Ascendis Pharma A/S (FRA:A71)

Ascendis Pharma Statistics

Total Valuation

Ascendis Pharma has a market cap or net worth of EUR 11.56 billion. The enterprise value is 11.82 billion.

Market Cap	11.56B
Enterprise Value	11.82B

Important Dates

The next estimated earnings date is Thursday, April 30, 2026.

Earnings Date	Apr 30, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+4.69%
Shares Change (QoQ)	+0.44%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	60.87M

Valuation Ratios

PE Ratio	n/a
Forward PE	39.40
PS Ratio	16.05
PB Ratio	-70.99
P/TBV Ratio	n/a
P/FCF Ratio	254.53
P/OCF Ratio	214.46
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-51.83
EV / Sales	16.10
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	260.27

Financial Position

The company has a current ratio of 1.04

Current Ratio	1.04
Quick Ratio	0.72
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	19.20
Interest Coverage	-1.69

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-6.86%
Return on Invested Capital (ROIC)	-11.67%
Return on Capital Employed (ROCE)	-58.44%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	605,662
Profits Per Employee	-191,786
Employee Count	1,189
Asset Turnover	0.58
Inventory Turnover	0.32

Taxes

In the past 12 months, Ascendis Pharma has paid 15.38 million in taxes.

Income Tax	15.38M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +27.52% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+27.52%
50-Day Moving Average	191.82
200-Day Moving Average	172.71
Relative Strength Index (RSI)	45.66
Average Volume (20 Days)	8

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.78

Income Statement

In the last 12 months, Ascendis Pharma had revenue of EUR 720.13 million and -228.03 million in losses. Loss per share was -3.76.

Revenue	720.13M
Gross Profit	625.22M
Operating Income	-136.27M
Pretax Income	-212.65M
Net Income	-228.03M
EBITDA	-131.42M
EBIT	-136.27M
Loss Per Share	-3.76

Balance Sheet

The company has 616.04 million in cash and 871.79 million in debt, with a net cash position of -255.75 million.

Cash & Cash Equivalents	616.04M
Total Debt	871.79M
Net Cash	-255.75M
Net Cash Per Share	n/a
Equity (Book Value)	-162.82M
Book Value Per Share	-2.65
Working Capital	39.59M

Cash Flow

In the last 12 months, operating cash flow was 53.90 million and capital expenditures -8.49 million, giving a free cash flow of 45.41 million.

Operating Cash Flow	53.90M
Capital Expenditures	-8.49M
Depreciation & Amortization	4.86M
Net Borrowing	-21.96M
Free Cash Flow	45.41M
FCF Per Share	n/a

Margins

Gross margin is 86.82%, with operating and profit margins of -18.92% and -31.67%.

Gross Margin	86.82%
Operating Margin	-18.92%
Pretax Margin	-29.53%
Profit Margin	-31.67%
EBITDA Margin	-18.25%
EBIT Margin	-18.92%
FCF Margin	6.31%

Dividends & Yields

Ascendis Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.69%
Shareholder Yield	-4.69%
Earnings Yield	-1.97%
FCF Yield	0.39%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Ascendis Pharma has an Altman Z-Score of 1.17 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.17
Piotroski F-Score	4